Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.81 |
| ▸ | NPC1 | O15118 | 9/20 | 0.81 |
| ▸ | RAB9A | P51151 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 7/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.81 |
| ▸ | HTT | P42858 | 4/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | RELA | Q04206 | 3/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | STAT1 | P42224 | 1/20 | 0.81 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.81 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.81 |
| ▸ | MMP2 | P08253 | 3/20 | 0.61 |
| ▸ | MMP9 | P14780 | 3/20 | 0.61 |
| ▸ | MMP8 | P22894 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324182 | 0.92 | NPBWR1 (0.73) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5566197 | 0.88 | NPC1 (0.78) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL465462 | 0.86 | NPBWR1 (0.61) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL17255153 | 0.85 | RAB9A (0.61) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13856173 | 0.85 | NPBWR1 (0.80) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL31060181 | 0.85 | CHEK2 (0.82) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL2244677 | 0.85 | NPBWR1 (0.60) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6324185 | 0.85 | NPBWR1 (0.86) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL12470997 | 0.84 | NPBWR1 (0.82) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL28483088 | 0.83 | NPC1 (0.71) | NPBWR1NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NAT UNIV IND COOP FOUND (KR) | 2015-12-24 | — | — | US | disclosed |
| US-9155690-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-10-13 | — | — | US | disclosed |
| US-8889881-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | Pusan National University Industry —University Cooperation Foundation (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | Pusan National University Indusrtyuniversity (KR) | 2014-02-06 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | NPBWR1 1705/4885NPC1 3522/4885RAB9A 3882/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885NPC1 2477/4885RAB9A 3748/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885NPC1 2477/4885RAB9A 3748/4885 |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | NPBWR1 1193/4885NPC1 3207/4885RAB9A 4420/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885NPC1 3637/4885RAB9A 4325/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885NPC1 3637/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.